The oral fluorouracil prodrugs.
作者： D. Medgyesy , P. M. Hoff , R. A. Brito , M. Royce , R. Pazdur
DOI:
关键词:
摘要: Discussed herein are selected oral fluorinated pyrimidines that converted to 5-fluorouracil (5-FU) in vivo exert antitumor activity. These agents include capecitabine (Xeloda), tegafur-uracil (UFT) plus leucovorin (Orzel), and S-1 (BMS247616). offer the convenience of an orally administered therapy with potentially fewer toxic effects than conventional bolus regimens 5-FU leucovorin. provide prolonged exposure at lower peak concentrations observed intravenous administration may confer pharmacoeconomic advantages by reducing costs toxicity-related hospitalizations. also have potential for improved therapeutic activity achieving higher tumor or biochemically modulating 5-FU. Phase III trials patients advanced colorectal carcinomas comparing these
cancernetwork.com参考文章(14)
T R Buroker, M J O'Connell, H S Wieand, J E Krook, J B Gerstner, J A Mailliard, P L Schaefer, R Levitt, C G Kardinal, D H Gesme, Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Journal of Clinical Oncology. ,vol. 12, pp. 14- 20 ,(1994) , 10.1200/JCO.1994.12.1.14
J J Lokich, J D Ahlgren, J J Gullo, J A Philips, J G Fryer, A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. Journal of Clinical Oncology. ,vol. 7, pp. 425- 432 ,(1989) , 10.1200/JCO.1989.7.4.425
M. González-Barón, J. Feliu, I. de la Gándara, E. Espinosa, A. Colmenarejo, B. Martínez-Martínez, E. Blanco, C. García-Girón, F. Juárez, P. Garrido, A. Ordóñez, P. Zamora, Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. European Journal of Cancer. ,vol. 31, pp. 2215- 2219 ,(1995) , 10.1016/0959-8049(95)00487-4
Leonard B. Saltz, Cynthia G. Leichman, Charles W. Young, Franco M. Muggia, John A. Conti, Tara Spiess, Susan Jeffers, Lawrence P. Leichman, A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer Cancer. ,vol. 75, pp. 782- 785 ,(1995) , 10.1002/1097-0142(19950201)75:3<782::AID-CNCR2820750306>3.0.CO;2-I
Richard Pazdur, Yvonne Lassere, Enrique Diaz-Canton, Beth Bready, Dah H Ho, Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anti-Cancer Drugs. ,vol. 7, pp. 728- 733 ,(1996) , 10.1097/00001813-199609000-00002
Kazuo Ota, Tesuo Taguchi, Kiyoji Kimura, Report on nationwide pooled data and cohort investigation in UFT phase II study Cancer Chemotherapy and Pharmacology. ,vol. 22, pp. 333- 338 ,(1988) , 10.1007/BF00254241
Richard Pazdur, Yvonne Lassere, Enrique Diaz-Canton, Dah H. Ho, Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Cancer Investigation. ,vol. 16, pp. 145- 151 ,(1998) , 10.3109/07357909809050028
Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo, Masahiro Yamaguchi, Toshiyuki Kato, Kazuhiko Yonekura, Masakazu Fukushima, Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs. ,vol. 7, pp. 548- 557 ,(1996) , 10.1097/00001813-199607000-00010
Yuji Shimamoto, Masakazu Fukushima, Tetsuhiko Shirasaka, Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Research. ,vol. 53, pp. 4004- 4009 ,(1993)
R Pazdur, Y Lassere, V Rhodes, J A Ajani, S M Sugarman, Y Z Patt, D V Jones, A B Markowitz, J L Abbruzzese, B Bready, Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. Journal of Clinical Oncology. ,vol. 12, pp. 2296- 2300 ,(1994) , 10.1200/JCO.1994.12.11.2296